TABLE 1

Treatment . | Percentage of viable islets^{*}. | . | . | . | ||
---|---|---|---|---|---|---|

. | Unmodified . | Ad-LacZ . | Ad-MnSOD . | |||

Alloxan | 10% (n = 112) | 4% (n = 102) | 95% (n = 110) | |||

SNAP | 15% (n = 105) | 20% (n = 100) | 22% (n = 90) | |||

Cytokines | 20% (n = 98) | 29% (n = 104) | 66% (n = 96) |

Treatment . | Percentage of viable islets^{*}. | . | . | . | ||
---|---|---|---|---|---|---|

. | Unmodified . | Ad-LacZ . | Ad-MnSOD . | |||

Alloxan | 10% (n = 112) | 4% (n = 102) | 95% (n = 110) | |||

SNAP | 15% (n = 105) | 20% (n = 100) | 22% (n = 90) | |||

Cytokines | 20% (n = 98) | 29% (n = 104) | 66% (n = 96) |

*

Percentage of islets was determined by dividing the number of viable islets remaining after treatment (those with <500 dead cells) divided by the total number of islets tested per treatment (*n*). Results are from three separate experiments of the three different islet groups.

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.